Literature DB >> 1720699

Further characterization of the loop structure of platelet glycoprotein IIIa: partial mapping of functionally significant glycoprotein IIIa epitopes.

W C Kouns1, P J Newman, K J Puckett, A A Miller, C D Wall, C F Fox, J M Seyer, L K Jennings.   

Abstract

Glycoprotein (GP) IIb-IIIa serves as the platelet fibrinogen receptor. Studies of the tertiary structure of GPIIIa have shown that the protein has a large loop structure of at least 325 amino acids in length. To further characterize this loop structure, intact platelets were digested with alpha-chymotrypsin. Digestion products were examined using the anti-GPIIIa monoclonal antibodies (MoAbs) AP3, D3GP3, and C5GP3, as well as the human alloantibody, anti-PLA1. AP3 recognized GPIIIa digestion products of 109, 95, and 68 Kd. D3GP3 and C5GP3 recognized an additional band of 51 Kd. Time course digestions demonstrated that the 51-Kd fragment was generated by proteolysis of the 68-Kd peptide. Sequence analysis of the reduced 51-Kd peptide showed that this fragment began at amino acid 422. The nonreduced 51-Kd peptide was reactive with antibodies directed against the first 13 amino acids of GPIIIa, demonstrating the presence of a covalently attached N-terminal peptide. These data suggest that: (1) the minimum length of the loop structure is at least 384 amino acids; (2) the AP3 epitope is formed at least in part by a determinant contained within residues 348 to 421; and (3) the D3GP3 and C5GP3 epitopes are contained within amino acids 422 to 692 of GPIIIa, a region that may be flexible and involved in conformational changes that occur after ligand binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720699

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation.

Authors:  W Beau Mitchell; Jihong Li; Marta Murcia; Nathalie Valentin; Peter J Newman; Barry S Coller
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

2.  Tests of the extension and deadbolt models of integrin activation.

Authors:  Jieqing Zhu; Brian Boylan; Bing-Hao Luo; Peter J Newman; Timothy A Springer
Journal:  J Biol Chem       Date:  2007-02-13       Impact factor: 5.157

3.  Proteolytic degradation of the RGD-binding and non-RGD-binding conformers of human platelet integrin glycoprotein IIb/IIIa: clues for identification of regions involved in the receptor's activation.

Authors:  J J Calvete; K Mann; W Schäfer; R Fernandez-Lafuente; J M Guisán
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

4.  Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin.

Authors:  Daniel W Bougie; Mark Rasmussen; Jieqing Zhu; Richard H Aster
Journal:  Blood       Date:  2012-04-06       Impact factor: 22.113

5.  Interaction of disintegrins with the alpha IIb beta 3 receptor on resting and activated human platelets.

Authors:  M A McLane; M A Kowalska; L Silver; S J Shattil; S Niewiarowski
Journal:  Biochem J       Date:  1994-07-15       Impact factor: 3.857

6.  The importance of N-glycosylation on β3 integrin ligand binding and conformational regulation.

Authors:  Xiulei Cai; Aye Myat Myat Thinn; Zhengli Wang; Hu Shan; Jieqing Zhu
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

7.  The membrane-distal regions of integrin α cytoplasmic domains contribute differently to integrin inside-out activation.

Authors:  Aye Myat Myat Thinn; Zhengli Wang; Jieqing Zhu
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.